TY - JOUR
T1 - Pharmacists’ experience with prescribing hormonal contraception in Oregon
AU - Rodriguez, Maria I.
AU - Biel, Frances M.
AU - Swartz, Jonas J.
AU - Anderson, Lorinda
AU - Edelman, Alison B.
N1 - Funding Information:
Funding: Maria Rodriguez is a Women's Reproductive Health Research fellow (grant 1K12HD085809). REDcap through Oregon Health and Science University was used for this study, and as such this research was supported by National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR0002369. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2018 American Pharmacists Association®
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Objectives: To describe Oregon pharmacy practices in provision of hormonal contraception (HC) and evaluate if pharmacists’ motivation to prescribe changed after 6 and 12 months of experience. Methods: Pharmacists practicing in Oregon who underwent the mandatory HC training were eligible to take this survey. The survey was launched 6 months after policy implementation; pharmacists who responded to the initial survey were eligible to be queried again at 12 months. Survey responses were anonymous, but pharmacists received a unique identifier so that responses could be linked between the 2 surveys. The survey consisted of pharmacy and pharmacist demographics and questions exploring attitudes toward prescribing HC and prescribing practices (e.g., cost, time needed for visit) and volume estimates. Descriptive statistics were used to analyze responses as well as the differences in key outcomes between 6 and 12 months. Results: A total of 732 pharmacists were eligible to take the survey; 121 pharmacists responded to the 6-month survey (16.5% response rate), and 62 completed the 12-month survey (52% response rate). A large increase in the distribution of pharmacists prescribing HC by zip code occurred between 6 and 12 months: 19% and 63%, respectively. At both 6 and 12 months, almost one-half of all pharmacists were billing insurance for the visit, and the average visit took less than 30 minutes. The top 3 motivators for providing HC did not change over time and included increasing access, reducing unintended pregnancy, and increasing pharmacist scope of practice. Conclusion: One year after program implementation, pharmacist prescribing of HC continues to increase and is distributed widely across the state. A geographically diverse sample of Oregon pharmacists began prescribing of hormonal contraception within 12 months of Oregon's implementation of the new pharmacist provision policy. Their experience and the success of the program provide a roadmap for pharmacist participation to increase access to hormonal contraception.
AB - Objectives: To describe Oregon pharmacy practices in provision of hormonal contraception (HC) and evaluate if pharmacists’ motivation to prescribe changed after 6 and 12 months of experience. Methods: Pharmacists practicing in Oregon who underwent the mandatory HC training were eligible to take this survey. The survey was launched 6 months after policy implementation; pharmacists who responded to the initial survey were eligible to be queried again at 12 months. Survey responses were anonymous, but pharmacists received a unique identifier so that responses could be linked between the 2 surveys. The survey consisted of pharmacy and pharmacist demographics and questions exploring attitudes toward prescribing HC and prescribing practices (e.g., cost, time needed for visit) and volume estimates. Descriptive statistics were used to analyze responses as well as the differences in key outcomes between 6 and 12 months. Results: A total of 732 pharmacists were eligible to take the survey; 121 pharmacists responded to the 6-month survey (16.5% response rate), and 62 completed the 12-month survey (52% response rate). A large increase in the distribution of pharmacists prescribing HC by zip code occurred between 6 and 12 months: 19% and 63%, respectively. At both 6 and 12 months, almost one-half of all pharmacists were billing insurance for the visit, and the average visit took less than 30 minutes. The top 3 motivators for providing HC did not change over time and included increasing access, reducing unintended pregnancy, and increasing pharmacist scope of practice. Conclusion: One year after program implementation, pharmacist prescribing of HC continues to increase and is distributed widely across the state. A geographically diverse sample of Oregon pharmacists began prescribing of hormonal contraception within 12 months of Oregon's implementation of the new pharmacist provision policy. Their experience and the success of the program provide a roadmap for pharmacist participation to increase access to hormonal contraception.
UR - http://www.scopus.com/inward/record.url?scp=85052724608&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052724608&partnerID=8YFLogxK
U2 - 10.1016/j.japh.2018.06.020
DO - 10.1016/j.japh.2018.06.020
M3 - Article
C2 - 30190201
AN - SCOPUS:85052724608
SN - 1544-3191
VL - 58
SP - 608
EP - 613
JO - Journal of the American Pharmaceutical Association. American Pharmaceutical Association
JF - Journal of the American Pharmaceutical Association. American Pharmaceutical Association
IS - 6
ER -